ES2127133A1 - Use of 2,5-dihydroxybenzenesulphonic derivatives for the manufacture of drugs intended for the treatment and prevention of Alzheimer's disease - Google Patents

Use of 2,5-dihydroxybenzenesulphonic derivatives for the manufacture of drugs intended for the treatment and prevention of Alzheimer's disease

Info

Publication number
ES2127133A1
ES2127133A1 ES09700827A ES9700827A ES2127133A1 ES 2127133 A1 ES2127133 A1 ES 2127133A1 ES 09700827 A ES09700827 A ES 09700827A ES 9700827 A ES9700827 A ES 9700827A ES 2127133 A1 ES2127133 A1 ES 2127133A1
Authority
ES
Spain
Prior art keywords
dihydroxybenzenesulphonic
alzheimer
disease
derivatives
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09700827A
Other languages
Spanish (es)
Other versions
ES2127133B1 (en
Inventor
Soler Jose Esteve
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of ES2127133A1 publication Critical patent/ES2127133A1/en
Application granted granted Critical
Publication of ES2127133B1 publication Critical patent/ES2127133B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Abstract

Use of 2,5-dihydroxybenzenesulphonic derivatives of general formula I, in which R represents H or SO-3 B represents Ca++ or H2N+ (C2H5)2 n represents 1 or 2 and m represents 1 or 2, for the manufacture of drugs intended to prevent the formation of the amyloid protein associated with Alzheimer's disease.
ES9700827A 1996-04-03 1997-04-03 USE OF 2,5-DIHYDROXYBENZENOSPHONE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES INTENDED FOR THE TREATMENT AND PREVENTION OF ALZHEIMER DISEASE. Expired - Fee Related ES2127133B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9604181 1996-04-03

Publications (2)

Publication Number Publication Date
ES2127133A1 true ES2127133A1 (en) 1999-04-01
ES2127133B1 ES2127133B1 (en) 1999-12-01

Family

ID=9490864

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9700827A Expired - Fee Related ES2127133B1 (en) 1996-04-03 1997-04-03 USE OF 2,5-DIHYDROXYBENZENOSPHONE DERIVATIVES FOR THE MANUFACTURE OF MEDICINES INTENDED FOR THE TREATMENT AND PREVENTION OF ALZHEIMER DISEASE.

Country Status (1)

Country Link
ES (1) ES2127133B1 (en)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRASER et al. Effects of sulfate ions on Alzheimer beta/A4 Peptide Assemblies: Implications for Amyloid Fibril-Proteoglycan Interactions. Journal of Neurochemistry, 1992, Vol. 59, no 4, paginas 1531-1540. *
KISILEVSKY et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nature Medicine, Vol. 1, no 2, Febrero 1995, paginas 143-148, resumen y discusion. *
LEVEUGLE et al. Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport, Vol. 5, no 11, 27 Junio 1994, paginas 1389-1392. *
NARINDRASORASAK et al. High Affinity Interactions between the Alzheimer's beta-amyloid precursor proteins and the basement Membrane form of heparan sulfate proteoglycan. Journal of Biological Chemistry, Vol. 266, no 20, 1991, paginas 12878-12883. *
SNOW et al. Proteoglycans in the Pathogenesis of Alzheimer's Disease and other Amyloidoses. Neurobiology of Aging, Vol. 10, 1989, paginas 481-497. *

Also Published As

Publication number Publication date
ES2127133B1 (en) 1999-12-01

Similar Documents

Publication Publication Date Title
TR200002773T2 (en) Smilagen and anzurogenin-D and their use for the treatment of Alzheimer's.
MXPA02011303A (en) Liquid pharmaceutical composition containing an erythropoietin derivate.
TW264480B (en)
BG101118A (en) Therapeutical compounds
IL99912A0 (en) Cyclosporins,their preparation and pharmaceutical compositions containing them
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
FI961809A0 (en) Novel (R) -5-carbamoyl-8-fluoro-3-N, N-disubstituted amino 3,4-dihydro-2H-1-benzopyrans
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
BR0014381A (en) Derivatives of 5-beta-sapogenin and pseudosapogenin and their use in the treatment of dementia
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
BG103474A (en) Application of derivatives of 7-(2-oxa-5,8-diazobicyclo[4,3,0]non-8-8-yl)-quinoloncarboxylic acid and naphthyridoncarboxylic acid in the therapy of helicobacter pylor infections and the gastroduodenal diseases related to them
RS8504A (en) Novel cyclohexil sulphones
WO1996022305A3 (en) Modified peptides
BR9814945A (en) Use of phanquinone for the treatment of alzheimer's disease, pharmaceutical composition and kit
NO983177L (en) Use of the 1-enantiomer of centroman for the preparation of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
MX9707642A (en) Pharmaceutical agents for the treatment of alzheimer's disease.
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
PT1152762E (en) USE OF DEOXYGEGANIN IN THE TREATMENT OF ALZHEIMER'S DEMENTIA
DK1040191T3 (en) RANTES mutants and their therapeutic uses
ES2127133A1 (en) Use of 2,5-dihydroxybenzenesulphonic derivatives for the manufacture of drugs intended for the treatment and prevention of Alzheimer's disease
HK1050203A1 (en) Novel fusidic acid derivatives.
AU2177401A (en) Combination of riluzole and gabapentin and use thereof as medicine

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19990401

Kind code of ref document: A1

Effective date: 19990401

FD1A Patent lapsed

Effective date: 20020401